全文获取类型
收费全文 | 1409521篇 |
免费 | 115799篇 |
国内免费 | 3332篇 |
专业分类
耳鼻咽喉 | 18372篇 |
儿科学 | 46596篇 |
妇产科学 | 41078篇 |
基础医学 | 200861篇 |
口腔科学 | 37759篇 |
临床医学 | 126080篇 |
内科学 | 284475篇 |
皮肤病学 | 33475篇 |
神经病学 | 116957篇 |
特种医学 | 53875篇 |
外国民族医学 | 464篇 |
外科学 | 210730篇 |
综合类 | 32766篇 |
现状与发展 | 3篇 |
一般理论 | 487篇 |
预防医学 | 110099篇 |
眼科学 | 31502篇 |
药学 | 98529篇 |
1篇 | |
中国医学 | 3349篇 |
肿瘤学 | 81194篇 |
出版年
2021年 | 10855篇 |
2019年 | 11673篇 |
2018年 | 16593篇 |
2017年 | 12693篇 |
2016年 | 14290篇 |
2015年 | 16039篇 |
2014年 | 22584篇 |
2013年 | 33433篇 |
2012年 | 45442篇 |
2011年 | 47966篇 |
2010年 | 28188篇 |
2009年 | 27076篇 |
2008年 | 44367篇 |
2007年 | 46864篇 |
2006年 | 47437篇 |
2005年 | 45906篇 |
2004年 | 43796篇 |
2003年 | 41733篇 |
2002年 | 40227篇 |
2001年 | 73025篇 |
2000年 | 74554篇 |
1999年 | 61590篇 |
1998年 | 17002篇 |
1997年 | 15439篇 |
1996年 | 15599篇 |
1995年 | 14803篇 |
1994年 | 13407篇 |
1993年 | 12595篇 |
1992年 | 45850篇 |
1991年 | 43487篇 |
1990年 | 41506篇 |
1989年 | 39567篇 |
1988年 | 36190篇 |
1987年 | 35363篇 |
1986年 | 32874篇 |
1985年 | 31290篇 |
1984年 | 23836篇 |
1983年 | 20026篇 |
1982年 | 12213篇 |
1981年 | 10786篇 |
1979年 | 20706篇 |
1978年 | 14588篇 |
1977年 | 12101篇 |
1976年 | 11377篇 |
1975年 | 11630篇 |
1974年 | 14000篇 |
1973年 | 13537篇 |
1972年 | 12642篇 |
1971年 | 11486篇 |
1970年 | 10923篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
261.
K.-C. Sung D.-C. Seo S.-J. Lee M.-Y. Lee S.H. Wild C.D. Byrne 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(5):489-495
Background and aims
It is not known whether non alcoholic fatty liver disease (NAFLD) is a risk factor for diabetes in non obese, non centrally-obese subjects. Our aim was to investigate relationships between fatty liver, insulin resistance and a biomarker score for liver fibrosis with incident diabetes at follow up, in subjects who were neither obese nor centrally-obese.Methods and results
As many as 70,303 subjects with a body mass index (BMI) < 25 kg/m2 and without diabetes were followed up for a maximum of 7.9 years. At baseline, fatty liver was identified by liver ultrasound, insulin resistance (IR) by homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.0, and central obesity by waist circumference (waist circumference ≥90 cm (men) and ≥85 cm (women). The Fibrosis-4 (FIB-4 score) was used to estimate extent of liver fibrosis. Cox proportional hazards models adjusted for confounders were used to estimate hazard ratios (aHRs) for incident diabetes. As many as 852 incident cases of diabetes occurred during follow up (median [IQR] 3.71 [2.03] years). Mean ± SD BMI was 22.8 ± 1.8 and 21.7 ± 2.0 kg/m2 in subjects with and without diabetes at follow up. In subjects without central obesity and with fatty liver, aHRs (95% CI) for incident diabetes at follow up were 2.17 (1.56, 3.03) for men, and 2.86 (1.50,5.46) for women. Similar aHRs for incident diabetes occurred with fatty liver, IR and the highest quartile of FIB-4 combined, in men; and there was a non significant trend toward increased risk in women.Conclusions
In normal weight, non-centrally obese subjects NAFLD is an independent risk factor for incident diabetes. 相似文献262.
Ebadi Maryam Bhanji Rahima A. Mazurak Vera C. Montano-Loza Aldo J. 《Journal of gastroenterology》2019,54(10):845-859
Journal of Gastroenterology - Sarcopenia (severe muscle depletion) is a prevalent muscle abnormality in patients with cirrhosis that confers poor prognosis both pre- and post-liver transplantation.... 相似文献
263.
John P. Sundberg Kathleen A. Silva Victoria E. Kennedy John J. Wilson Nicholas E. Gott Beth A. Sundberg Derry C. Roopenian 《Experimental dermatology》2019,28(9):1091-1093
2‐deoxy D‐glucose (2DG) was tested for efficacy in treating alopecia areata using the C3H/HeJ skin graft model. 2DG has proven to be efficacious in treatment of various mouse models of autoimmunity with minimal serious side effects noted. This agent has been shown to normalize abnormally activated T‐cell populations while also preventing cell surface expression of NKG2D; key factors defining alopecia areata disease progression. Daily oral ingestion of 2DG via drinking water to mice with patchy or diffuse alopecia areata for 16 weeks failed to prevent expansion of alopecia or cause regrowth of hair in treated mice. Histologically, there were no differences between treated and control groups. These results indicate that, while 2DG is effective for some autoimmune diseases, it was not efficacious for the cell‐mediated autoimmune mouse disease, alopecia areata. 相似文献
264.
265.
266.
267.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
268.
Diffuse dermal angiomatosis: a contributory factor to ulceration in a patient with renal transplant
下载免费PDF全文
![点击此处可从《Clinical and experimental dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
We present the case of a 54‐year‐old patient with renal transplant who developed unusual vascular changes on the forearm distal to a functioning arteriovenous fistula, as well as a painful ulcerated lesion on her anterior abdominal wall. We believe that the diffuse dermal angioendotheliomatosis variant of reactive angioendotheliomatosis had a role in the pathogenesis of this patient's lesions. 相似文献
269.
270.
Bob C. Mulder Merel A. A. van Lelyveld Sigrid C. J. M. Vervoort Anne Marike Lokhorst Cees M. J. van Woerkum Jan M. Prins 《Health communication》2016,31(1):35-46
Since the introduction of cART (combination antiretroviral therapy), HIV has evolved into a chronic disease such that it requires lifelong medical treatment to which patients must adhere. Communication with health care providers is pivotal in supporting patients to adapt to having HIV and adhering to treatment, in order to maintain health and quality of life. Previous research indicates that communication is optimal when it matches patient preferences for information exchange, relationship establishment, and involvement in treatment decisions. The aim of the present study is to explore HIV patient communication preferences as well as patient experiences with their providers (not) matching their preferences. A second aim is to explore provider beliefs about patient preferences and provider views on optimal communication. Data were collected through interviews with 28 patients and 11 providers from two academic hospitals. Results indicate that patient preferences reflect their cognitive, emotional, and practical needs such that patients look to increase their sense of control over their HIV. Patients aim to further increase their sense of control (by proxy) through their relationship with their providers and through their decisional involvement preferences. Providers are well aware of patient communication preferences but do not explicate underlying control needs. Implications for clinical practice are discussed. 相似文献